127 related articles for article (PubMed ID: 20183431)
1. Drug-drug interaction prediction assessment.
Zhou J; Qin Z; Sara QK; Kim S; Wang Z; Hall SD; Li L
J Biopharm Stat; 2009 Jul; 19(4):641-57. PubMed ID: 20183431
[TBL] [Abstract][Full Text] [Related]
2. Drug-drug interaction prediction: a Bayesian meta-analysis approach.
Li L; Yu M; Chin R; Lucksiri A; Flockhart DA; Hall SD
Stat Med; 2007 Sep; 26(20):3700-21. PubMed ID: 17357990
[TBL] [Abstract][Full Text] [Related]
3. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions.
Guest EJ; Aarons L; Houston JB; Rostami-Hodjegan A; Galetin A
Drug Metab Dispos; 2011 Feb; 39(2):170-3. PubMed ID: 21036951
[TBL] [Abstract][Full Text] [Related]
4. A Bayesian meta-analysis on published sample mean and variance pharmacokinetic data with application to drug-drug interaction prediction.
Yu M; Kim S; Wang Z; Hall S; Li L
J Biopharm Stat; 2008; 18(6):1063-83. PubMed ID: 18991108
[TBL] [Abstract][Full Text] [Related]
5. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
[TBL] [Abstract][Full Text] [Related]
6. A new probabilistic rule for drug-dug interaction prediction.
Zhou J; Qin Z; Quinney SK; Kim S; Wang Z; Yu M; Chien JY; Lucksiri A; Hall SD; Li L
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):1-18. PubMed ID: 19156505
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability considerations in evaluating drug-drug interactions using the population pharmacokinetic approach.
Duan JZ; Jackson AJ; Zhao P
J Clin Pharmacol; 2011 Jul; 51(7):1087-100. PubMed ID: 20864622
[TBL] [Abstract][Full Text] [Related]
8. Predicting event times in clinical trials when treatment arm is masked.
Donovan JM; Elliott MR; Heitjan DF
J Biopharm Stat; 2006 May; 16(3):343-56. PubMed ID: 16724489
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based inhibition of cytochrome P450 enzymes: an evaluation of early decision making in vitro approaches and drug-drug interaction prediction methods.
Grime KH; Bird J; Ferguson D; Riley RJ
Eur J Pharm Sci; 2009 Feb; 36(2-3):175-91. PubMed ID: 19013237
[TBL] [Abstract][Full Text] [Related]
10. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. II. In vitro-in vivo correlation with ketoconazole.
Lu C; Hatsis P; Berg C; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1255-60. PubMed ID: 18381489
[TBL] [Abstract][Full Text] [Related]
11. Quantitative prediction of metabolic inhibition of midazolam by itraconazole and ketoconazole in rats: implication of concentrative uptake of inhibitors into liver.
Yamano K; Yamamoto K; Kotaki H; Sawada Y; Iga T
Drug Metab Dispos; 1999 Mar; 27(3):395-402. PubMed ID: 10064572
[TBL] [Abstract][Full Text] [Related]
12. Sample size calculation for the Power Model for dose proportionality studies.
Sethuraman VS; Leonov S; Squassante L; Mitchell TR; Hale MD
Pharm Stat; 2007; 6(1):35-41. PubMed ID: 17323313
[TBL] [Abstract][Full Text] [Related]
13. Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.
Lu C; Balani SK; Qian MG; Prakash SR; Ducray PS; von Moltke LL
J Pharmacol Exp Ther; 2010 Feb; 332(2):562-8. PubMed ID: 19889796
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys.
Ogasawara A; Kume T; Kazama E
Drug Metab Dispos; 2007 Mar; 35(3):410-8. PubMed ID: 17142564
[TBL] [Abstract][Full Text] [Related]
15. The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions.
Obach RS; Walsky RL; Venkatakrishnan K; Gaman EA; Houston JB; Tremaine LM
J Pharmacol Exp Ther; 2006 Jan; 316(1):336-48. PubMed ID: 16192315
[TBL] [Abstract][Full Text] [Related]
16. Assessment of equivalence using a concordance correlation coefficient in a repeated measurements design.
Quiroz J
J Biopharm Stat; 2005; 15(6):913-28. PubMed ID: 16279351
[TBL] [Abstract][Full Text] [Related]
17. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
Reitman ML; Chu X; Cai X; Yabut J; Venkatasubramanian R; Zajic S; Stone JA; Ding Y; Witter R; Gibson C; Roupe K; Evers R; Wagner JA; Stoch A
Clin Pharmacol Ther; 2011 Feb; 89(2):234-42. PubMed ID: 21191377
[TBL] [Abstract][Full Text] [Related]
18. Confidence intervals for ratios of AUCs in the case of serial sampling: a comparison of seven methods.
Jaki T; Wolfsegger MJ; Ploner M
Pharm Stat; 2009; 8(1):12-24. PubMed ID: 18407562
[TBL] [Abstract][Full Text] [Related]
19. Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats.
Takedomi S; Matsuo H; Yamano K; Yamamoto K; Iga T; Sawada Y
Drug Metab Dispos; 1998 Apr; 26(4):318-23. PubMed ID: 9531518
[TBL] [Abstract][Full Text] [Related]
20. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
